119 related articles for article (PubMed ID: 22312850)
1. [Clinical significance of cytochrome P450 genetic polymorphism--part IV. Cytochrome P450 3A4 and 3A5].
Duricová J; Grundmann M
Ceska Slov Farm; 2011 Dec; 60(6):276-82. PubMed ID: 22312850
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 3A polymorphisms and immunosuppressive drugs.
Thervet E; Legendre C; Beaune P; Anglicheau D
Pharmacogenomics; 2005 Jan; 6(1):37-47. PubMed ID: 15723604
[TBL] [Abstract][Full Text] [Related]
3. Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5.
Niwa T; Murayama N; Emoto C; Yamazaki H
Curr Drug Metab; 2008 Jan; 9(1):20-33. PubMed ID: 18220568
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 3A: genetic polymorphisms and inter-ethnic differences.
Krishna DR; Shekar MS
Methods Find Exp Clin Pharmacol; 2005 Oct; 27(8):559-67. PubMed ID: 16273136
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.
Anglicheau D; Legendre C; Beaune P; Thervet E
Pharmacogenomics; 2007 Jul; 8(7):835-49. PubMed ID: 18240909
[TBL] [Abstract][Full Text] [Related]
6. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
He P; Court MH; Greenblatt DJ; Von Moltke LL
Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
[TBL] [Abstract][Full Text] [Related]
7. Marmoset Cytochrome P450 3A4 Ortholog Expressed in Liver and Small-Intestine Tissues Efficiently Metabolizes Midazolam, Alprazolam, Nifedipine, and Testosterone.
Uehara S; Uno Y; Nakanishi K; Ishii S; Inoue T; Sasaki E; Yamazaki H
Drug Metab Dispos; 2017 May; 45(5):457-467. PubMed ID: 28196829
[TBL] [Abstract][Full Text] [Related]
8. Effects of histidine-tag on recombinant human cytochrome P450 3A5 catalytic activity in reconstitution systems.
Emoto C; Murayama N; Wakiya S; Yamazaki H
Drug Metab Lett; 2009 Dec; 3(4):207-11. PubMed ID: 19702542
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid Aalpha2/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics.
Ma B; Polsky-Fisher SL; Vickers S; Cui D; Rodrigues AD
Drug Metab Dispos; 2007 Aug; 35(8):1301-7. PubMed ID: 17460031
[TBL] [Abstract][Full Text] [Related]
10. Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus.
Dostalek M; Court MH; Yan B; Akhlaghi F
Br J Pharmacol; 2011 Jul; 163(5):937-47. PubMed ID: 21323901
[TBL] [Abstract][Full Text] [Related]
11. Functional gene variants of CYP3A4.
Werk AN; Cascorbi I
Clin Pharmacol Ther; 2014 Sep; 96(3):340-8. PubMed ID: 24926778
[TBL] [Abstract][Full Text] [Related]
12. The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil.
Ku HY; Ahn HJ; Seo KA; Kim H; Oh M; Bae SK; Shin JG; Shon JH; Liu KH
Drug Metab Dispos; 2008 Jun; 36(6):986-90. PubMed ID: 18308836
[TBL] [Abstract][Full Text] [Related]
13. Statin regulation of CYP3A4 and CYP3A5 expression.
Willrich MA; Hirata MH; Hirata RD
Pharmacogenomics; 2009 Jun; 10(6):1017-24. PubMed ID: 19530969
[TBL] [Abstract][Full Text] [Related]
14. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 3A5 polymorphism affects the metabolism of sorafenib and its toxicity for hepatocellular carcinoma cells
Song HY; Xia JS; Chen YG; Chen L
Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S646-S653. PubMed ID: 34784831
[TBL] [Abstract][Full Text] [Related]
16. The X-Ray Crystal Structure of the Human Mono-Oxygenase Cytochrome P450 3A5-Ritonavir Complex Reveals Active Site Differences between P450s 3A4 and 3A5.
Hsu MH; Savas U; Johnson EF
Mol Pharmacol; 2018 Jan; 93(1):14-24. PubMed ID: 29093019
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 3A5 polymorphism affects the metabolism of sorafenib and its toxicity for hepatocellular carcinoma cells
Song HY; Xia JS; Chen YG; Chen L
Hum Exp Toxicol; 2022; 41():9603271221080236. PubMed ID: 35099304
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes.
Fahmi OA; Kish M; Boldt S; Obach RS
Drug Metab Dispos; 2010 Sep; 38(9):1605-11. PubMed ID: 20566695
[TBL] [Abstract][Full Text] [Related]
19. Drug interactions of thalidomide with midazolam and cyclosporine A: heterotropic cooperativity of human cytochrome P450 3A5.
Okada Y; Murayama N; Yanagida C; Shimizu M; Guengerich FP; Yamazaki H
Drug Metab Dispos; 2009 Jan; 37(1):18-23. PubMed ID: 18948377
[TBL] [Abstract][Full Text] [Related]
20. Tacrolimus Dose Optimization Strategy for Refractory Ulcerative Colitis Based on the Cytochrome P450 3A5 Polymorphism Prediction Using Trough Concentration after 24 Hours.
Onodera M; Endo K; Naito T; Moroi R; Kuroha M; Kanazawa Y; Kimura T; Shiga H; Kakuta Y; Negoro K; Kinouchi Y; Shimosegawa T
Digestion; 2018; 97(1):90-96. PubMed ID: 29393157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
